Pharma major Lupin’s (Lupin) Japanese subsidiary - Kyowa Pharmaceutical Industry (Kyowa), has entered into an agreement with I’rom Holdings Company (IH), an integrated Japanese healthcare provider, to acquire up to 100% of the outstanding shares of its subsidiary I'rom Pharmaceutical Company (IP).
Established in 1947, IP is a specialty Injectables Company headquartered in Tokyo. For the fiscal year ended March 2011, IP recorded sales revenues of JPY 5,361 million. IP has a significant presence in the DPC hospitals within Japan. Injectable products enjoy a significant usage in the DPC Hospital segment and generic injectable penetration is slated to grow significantly in future. There are currently over 1,400 DPC hospitals in Japan, covering over 35% of all hospital beds nationwide, and a market size of $11 billion.
Also, in a separate development, Kyowa has entered into a strategic alliance involving comprehensive operational support to be provided by IH's site management organization (SMO) subsidiary I’rom Company (Irom) for clinical studies conducted by Kyowa for the Japanese market. Irom is known as the pioneer of the SMO business in Japan, and the alliance seeks to utilize Irom's expertise to support Kyowa.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. Lupin has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: